Fresenius Medical and Vectren Receive Buy Ratings

Here are today's top Wall Street analyst ratings where finbox.io's unbiased fair value estimates support the recommendation.

Top Upgrades and Buy Ratings

  • JPMorgan Chase reiterated Fresenius Medical Care (NYSE:FMS) at Buy. Shares currently have 20% upside. ‘FMS

  • RBC Capital raised its price target for GMS (NYSE:GMS) to $32 per share and set an Outperform rating. Finbox.io's six valuation analyses also conclude a $32 intrinsic value implying almost 18% upside. ‘GMS

  • Piper Jaffray upgraded Kroger (NYSE:KR) from Underweight to Neutral. The new rating is generally supported by the company's fundamentals. ‘KR

  • Citigroup upgraded Vectren Corp. (NYSE:VVC) from Neutral to Buy. Nine valuation models imply a fair value of $59 per share implying the stock is currently 13% undervalued. ‘VVC

Top Downgrades

  • Sandler O'Neill downgraded Liberty Property Trust (NYSE:LPT) from Hold to Sell. Shares are currently trading at a 11% premium. ‘LPT

  • Morgan Stanley downgraded Zayo Group Holdings (NYSE:ZAYO) from Overweight to Equal Weight. Five valuation models imply the stock is 8% overvalued.
    ‘ZAYO

  • William Blair downgraded ICF International (Nasdaq:ICFI) from Outperform to Market Perform. Shares traded lower by nearly 7% following the downgrade. Ten valuation models conclude that the company still has a negative 5% margin of safety. ‘ICFI

Get Started Now!

Comments